Next Article in Journal
Antimicrobial Peptides Targeting Gram-Positive Bacteria
Next Article in Special Issue
Use of Capsaicin to Treat Pain: Mechanistic and Therapeutic Considerations
Previous Article in Journal
Preparation of Temozolomide-Loaded Nanoparticles for Glioblastoma Multiforme Targeting—Ideal Versus Reality
Previous Article in Special Issue
Targeting TRPM2 in ROS-Coupled Diseases
Open AccessReview

TRPV3 in Drug Development

1
Lilly Research Centre, Eli Lilly and Company Ltd., Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK
2
Covance Greenfield Laboratories, Greenfield, Indianapolis, IN 46140, USA
3
Lilly Research Laboratories, Eli Lilly and Company Inc., Indianapolis, IN 46285, USA
*
Author to whom correspondence should be addressed.
Academic Editors: Arpad Szallasi and Susan M. Huang
Pharmaceuticals 2016, 9(3), 55; https://doi.org/10.3390/ph9030055
Received: 1 July 2016 / Revised: 19 August 2016 / Accepted: 31 August 2016 / Published: 9 September 2016
Transient receptor potential vanilloid 3 (TRPV3) is a member of the TRP (Transient Receptor Potential) super-family. It is a relatively underexplored member of the thermo-TRP sub-family (Figure 1), however, genetic mutations and use of gene knock-outs and selective pharmacological tools are helping to provide insights into its role and therapeutic potential. TRPV3 is highly expressed in skin, where it is implicated in skin physiology and pathophysiology, thermo-sensing and nociception. Gain of function TRPV3 mutations in rodent and man have enabled the role of TRPV3 in skin health and disease to be particularly well defined. Pre-clinical studies provide some rationale to support development of TRPV3 antagonists for therapeutic application for the treatment of inflammatory skin conditions, itch and pain. However, to date, only one compound directed towards block of the TRPV3 receptor (GRC15300) has progressed into clinical trials. Currently, there are no known clinical trials in progress employing a TRPV3 antagonist. View Full-Text
Keywords: TRPV3; keratinocytes; itch; pain; Olmsted syndrome TRPV3; keratinocytes; itch; pain; Olmsted syndrome
Show Figures

Figure 1

MDPI and ACS Style

Broad, L.M.; Mogg, A.J.; Eberle, E.; Tolley, M.; Li, D.L.; Knopp, K.L. TRPV3 in Drug Development. Pharmaceuticals 2016, 9, 55.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop